ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

Jacky Vonderscher

  • Founder of Vonderscher&Co GmbH
  • Senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
  • Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
  • Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
  • Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
  • Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
  • Board member of Inatherys and ObsEva and SAB member of Inotrem

Jonathan Lieber, MBA, Chief Financial Officer

Jonathan Lieber

  • Responsible for all financial and accounting activities
  • 25 years of experience in financial and executive management at emerging and growth-stage life science companies and in investment banking
  • Significant experience in public and private capital raising for healthcare companies
  • Currently serving as Managing Director of Danforth Advisors LLC
  • Previously CFO of several public and private healthcare companies including: Histogenics (Nasdaq: HSGX), Metamark Genetics, Repligen (Nasdaq: REGN), Xcellerex (acquired by GE Healthcare) and Altus Pharmaceuticals (Nasdaq: ALTU)
  • Education: Stern School of Business of New York University (MBA) and Boston University (BSBA)

Dr. Nicolas Guyon-Gellin, MD, ESCP, Vice President Corporate Development & Strategy

Nicolas Guyon-Gellin

  • Responsible for Corporate development and strategy
  • Global expert in financial markets and Healthcare
  • Most recently equity research analyst for Morgan Stanley based in London covering various sized listed companies and involved in various Corporate banking activities
  • Former equity research analyst for Exane BNP and Amundi where he was in charge of global pharmaceuticals investment recommendations
  • Graduated from Paris V University as a General Practitioner with a Master degree from ESCP Europe

Dr Pietro Scalfaro, MD, MBA, Chief Medical Officer

Pietro Scalfaro

  • In charge of strategy and operational management of early-stage clinical drug development
  • Wide range experience in this role in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
  • Set up a Personalised Medicine Business Unit at Debiopharm Group and is involved in Swiss eHealth start-up companies
  • Physician, with a degree from the University of Lausanne, certificates in Paediatrics and Intensive Care, and holds an MBA

Dr Raphaël Darteil, PhD, VP Head of non-clinical Development

Rapahaël Darteil

  • Responsible for non-clinical development
  • More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
  • Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
  • COO and Member of the board at Genfit
  • Various positions in the department of Gene Therapy of Aventis both in France and in the US
  • Co-inventor of the patent protecting the use of Elafibranor (Phase III ongoing) for the treatment of NASH patients
  • He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Dr Eric Meldrum, PhD, Chief Scientific Officer

Eric Meldrum

  • Responsible for the strategy and operational management of pre-clinical drug discovery and development
  • Specialist in drug development, having worked for major pharmaceutical groups and biotechnology companies
  • Former Chief Scientific Officer at Genkyotex and at 3V Biosciences, where he developed portfolios of NOX-inhibiting molecules and of molecules targeting the replication of respiratory viruses respectively
  • Former Director of the Asthma Disease Biology Department at GSK, where he was accountable for the biology associated with more than a dozen drug research and development programmes through to Phase 2 of clinical trials